Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03990194 | Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate Cancer(LEPTO) | withdrawn | — | 0 | RECORDATI GROUPINDUSTRY | 0 | Oct 31, 2024 | clinicaltrials |
| NCT06218667 | A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Oct 31, 2024 |
| clinicaltrials |
| NCT05882305 | KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial | withdrawn | Early Phase 1 | 0 | Kousai Bio Co., Ltd.OTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT04523623 | Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated Forearm Injuries | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT04580836 | MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT05056805 | An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of Strength in Patients With Pancreatic or Stomach Cancer Receiving Chemoradiation Therapy Before Surgery, SurgeryStrong Study | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | withdrawn | Phase 1 / Phase 2 | 0 | University of ChicagoOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03417765 | Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas | withdrawn | Phase 1 / Phase 2 | 0 | GlyPharma TherapeuticsINDUSTRY | 0 | Oct 24, 2024 | clinicaltrials |
| NCT05177796 | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT04987281 | Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05589857 | A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Tolerant Users Undergoing Surgery to Reduce Post-operative Opioid Use | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05134740 | (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).(pediTACTAL) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT05488444 | A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted Intervention Using Patient Navigators or Routine Clinical Care | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT03238053 | Laser Treatment of Genito-urinary Syndrome in Women | withdrawn | N/A | 0 | Herning HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04583553 | Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients Using Vikor Scientific Urine-ID Testing Menu (IDTM) and Standard Laboratory Culture(VS-UrineID) | withdrawn | — | 0 | University of Kansas Medical CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05521178 | Cardiotoxicities in Patients Receiving BTKi | withdrawn | — | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Oct 15, 2024 | clinicaltrials |
| NCT06161493 | ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors | withdrawn | Phase 1 | 0 | Haider MahdiOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06638736 | A Randomized Controlled Trial Comparing Sutures vs Staples for High Tension Closures | withdrawn | N/A | 0 | University of Kansas Medical CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03990597 | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT04135326 | Transcranial Direct Current Stimulation in Reducing Pain in Cancer Patients With Chemotherapy Induced Peripheral Neuropathy | withdrawn | Early Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT04312191 | Using Meditation for Oncology Anxiety | withdrawn | N/A | 0 | Mellar Davis MDOTHER | 0 | Oct 8, 2024 | clinicaltrials |
| NCT05718297 | Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer(BOUNCE) | withdrawn | Phase 2 | 0 | ETOP IBCSG Partners FoundationNETWORK | 5 | Oct 8, 2024 | clinicaltrials |
| NCT05846165 | InveStigAting Bladder fiELd-cycLing imAging(ISABELLA) | withdrawn | N/A | 0 | University of AberdeenOTHER | 0 | Oct 8, 2024 | clinicaltrials |
| NCT01847495 | Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT02298816 | B-Cell Hematologic Malignancy Vaccination Registry(HMvax-Regist) | withdrawn | — | 0 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT04258969 | Pedaling at a Low-Moderate Intensity During Chemotherapy Administration | withdrawn | N/A | 0 | Rush University Medical CenterOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04982354 | Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Guenther KoehneOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06424717 | Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder) | withdrawn | Phase 2 | 0 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 0 | Sep 27, 2024 | clinicaltrials |
| NCT06427369 | An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Sep 27, 2024 | clinicaltrials |
| NCT03677024 | Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk Endometrial Carcinomas | withdrawn | N/A | 0 | Fudan UniversityOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT05518032 | Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT04322084 | Continuous Ambulatory Monitoring to Predict Elevated Risk of Infection in Children With Lymphoblastic Leukemia Undergoing Induction Chemotherapy (CAMPER-ALL) | withdrawn | — | 0 | St. Jude Children's Research HospitalOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT05707182 | 18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study | withdrawn | Early Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | Sep 25, 2024 | clinicaltrials |
| NCT00756795 | Increasing Physical Activity of Patients With Head and Neck Cancer (I-PAP Study)(I-PAP) | withdrawn | N/A | 0 | University of NebraskaOTHER | 0 | Sep 23, 2024 | clinicaltrials |
| NCT03448666 | ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases | withdrawn | Phase 2 | 0 | European Institute of OncologyOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT03989050 | Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors(SPICE) | withdrawn | — | 0 | University of CologneOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT04488159 | Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer(iMAGINE) | withdrawn | Phase 3 | 0 | Johannes Laengle, MD, PhDOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. | withdrawn | Phase 2 | 0 | Nykode Therapeutics ASAINDUSTRY | 0 | Sep 20, 2024 | clinicaltrials |
| NCT01174615 | Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth | withdrawn | — | 0 | University of Massachusetts, WorcesterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02745197 | A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer | withdrawn | Phase 2 | 0 | University of AlbertaOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT03459755 | Evaluating Race Specific AGE Accumulation As a Behavioral Biomarker Prostate Cancer Survivors | withdrawn | N/A | 0 | Medical University of South CarolinaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05356897 | Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | withdrawn | Phase 1 | 0 | Brown UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05757843 | Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT05773664 | Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT05823480 | Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT05849142 | Feasibility of Adaptive Radiation Therapy for Human-papilloma Virus-positive Oropharyngeal Cancer Patients on MRIdian Linac(OPC-V) | withdrawn | N/A | 0 | University of MiamiOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05854966 | CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT05929300 | A Yoga Program for Patients Undergoing Prostate Cancer Surgery | withdrawn | N/A | 0 | VA Office of Research and DevelopmentFED | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 31, 2024source: clinicaltrials